Management of psychiatric symptoms of parkinson’s disease

European Neurology

Volumn 36, Issue , 1996, Pages 49-54

  Miyoshi, Koho ^a   Ueki, Akinori ^b   Nagano, Osamu ^b  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Antiparkinsonian treatment; Depression; Parkinson s disease; Visual hallucination

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; LEVODOPA; NEUROLEPTIC AGENT;

ANXIETY; CIRCADIAN RHYTHM; CONFERENCE PAPER; DELUSION; DEPRESSION; HUMAN; IRRITABILITY; PARKINSON DISEASE; PRIORITY JOURNAL; VISUAL HALLUCINATION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; SEX DISTRIBUTION;

EID: 0030048498     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000118884     Document Type: Article

References (28)

1. Cummings JL: Depression and Parkinson's disease a review. Am J Psychiatry 1992:149:443-454.
2. Miyoshi K, Sato M, Takauchi S: Affective symptoms and hallucinations in Parkinson's disease. Annual Report of Research Committee of CNS Degenerative Disease. Ministry of Health and Welfare of Japan 1984, pp 328-334.
3. Santamaria J, Tolosa E, Valles A: Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986:36: 1130-1133.
4. Starkstein SE, Bertheir ML, Bolduc PK, Pre-ziosi TJ, Robinson RG: Depression in patients with early versus late onset of Parkinson’s disease. Neurology 1989;39:1441-1445.
5. Gotham AM, Brown RG, Marsden CD: Depression in Parkinson’s disease a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986:49:381-389.
6. Brown RC, MacCarthy B, Gotham AM, Der GJ, Marsden CD: Depression and disability in Parkinson's disease: A follow-up study of 132 cases. Psychol Med 1988;18:49-55.
7. Robins AH: Depression in patients with parkinsonism. Br J Psychiatry 1976:128:141-145.
8. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality. Neurology 1967; 17: 427-442.
9. Mindham RHS, Marsden CD, Parkes JD: Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med 1976:6:23-33.
10. Huber SJ, Eridenberg DI, Paulson GW, Shuttlcworth EC, Christy JA: The pattern of depressive symptoms varies with the progression of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:275-278.
11. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE: Anti-depressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980;62:210-219.
12. Laitmen L: Ucsipraminc in treatment of Parkinson's disease. Acta Neurol Scand 1969:45: 109-113.
13. Hargrave R, Ashford JW: Phenelzine treatment of depression in Parkinson's disease (letter). Am J Psychiatry 1992;149:1751-1752.
14. Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA: Selegiline use to prevent progression of Parkinson's disease. Arch Neurol 1989:46:1275-1279.
15. Abrams R: ECT for Parkinson's disease. Am J Psychiatry 1989;146:1391-1393.
16. Burke WJ, Peterson J, Rubin EH: Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease. Psychosomatic« 1988:29:341-346.
17. Oh JJ, Rummans TA, O'Conner MK, Ahlskog JE: Cognitive impairement after ECT in patients with Parkinson's disease and psychiatric illness (letter). Am J Psychiatry 1992:149:271.
18. Cclesia GG, Barr AN: Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970:23:193-201.
19. Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 1971:218:1915-1920.
20. Miyoshi K, Morita Y, Nishitani H, Noguchi S: Visual hallucination and illusion in parkinsonian patients under L-dopa and amantadine treatment. Proc 11th World Congr Neurol, Amsterdam 1977.
21. Nagano O, Takauchi S, Nishitani H, Miyoshi K: Hallucinatory symptoms in Parkinson's disease during treatment with anti-parkinsonian drugs. Clin Neurol (Tokyo) 1986:26:464-470.
22. Friedman A, Sienkiewicz J: Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991;84: 111-113.
23. Klawans H L: Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm 1988;27(suppl): 117-122.
24. Postma JV, Tilburg WV: Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975:23:212.
25. Schwab RS, England AC, Poskanzer DC, Young RR: Amantadine in the treatment of Parkinson's disease. JAMA 1969:208:1168-1170.
26. Tune LE, Damlouji NF, Holland A, Gardner TJ, Folstein MF, Coyle JT: Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 1981:ii:651 -653.
27. Weiner WJ, Koller WC, Perlik S, Nausieda PA, Klawans HL: Drug holiday and management of Parkinson's disease. Neurology 1980:30: 1257-1261.
28. Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 1989;39:1219-1221.